Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ITOS ITeos Therapeutics
20.770+0.470+2.32%
Close
02/03 16:00 ET
20.7700.0000.00%
Post Mkt Price 02/03 16:04 ET
High
21.500
Open
20.510
Turnover
5.56M
Low
20.080
Pre Close
20.300
Volume
266.14K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Great West Life Assurance Co. Can Invests $470,000 in ITeos Therapeutics, Inc. (NASDAQ:ITOS)
Great West Life Assurance Co. Can bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) during the third quarter, according to its most recent filing with the SEC. The firm bough
Roche CEO Drags Arcus, ITeos Lower After Comments on Cancer Trial
Short Interest in ITeos Therapeutics, Inc. (NASDAQ:ITOS) Grows By 5.0%
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 1,460,000 shares, a growth of
ITeos Therapeutics (NASDAQ:ITOS) Stock Price Down 3.5%
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating)'s share price fell 3.5% during trading on Monday . The company traded as low as $20.93 and last traded at $20.93. 36,725 shares changed hands durin
Allspring Global Investments Holdings LLC Cuts Stock Position in ITeos Therapeutics, Inc. (NASDAQ:ITOS)
Allspring Global Investments Holdings LLC cut its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) by 74.6% during the third quarter, according to its most recent Form 13F f
Analyzing ITeos Therapeutics (NASDAQ:ITOS) and Vigil Neuroscience (NASDAQ:VIGL)
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two compa
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Short Interest Up 9.8% in December
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,800,000 shar
ITeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Sees Large Increase in Short Interest
iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling
5 Value Stocks In The Healthcare Sector
What are Value Stocks?A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors ar
Company Overview
More
iTeos Therapeutics, Inc. engages in the development of biopharmaceutical therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
CEO： Mr. Michel Detheux, PhD
Market： NASDAQ
Listing Date： 07/24/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet